NASDAQ:OVID
Ovid Therapeutics Inc Stock News
$3.06
+0 (+0%)
At Close: May 31, 2024
3 Sorry Penny Stocks to Sell in May While You Still Can
01:09pm, Tuesday, 28'th May 2024
Investors should focus on these penny stocks to sell in May to avoid potential losses. While more affordable and often appealing to investors with limited capital, Penny stocks can also carry signific
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
06:00am, Monday, 20'th May 2024
No matter what anyone says, the very concept of penny stocks to buy must be treated with extreme skepticism. I'm not talking about having an aggressive mistrust toward such enterprises.
Ovid Therapeutics Inc. (NASDAQ:OVID) Expected to Earn Q2 2024 Earnings of ($0.25) Per Share
01:38am, Monday, 20'th May 2024
Ovid Therapeutics Inc. (NASDAQ:OVID – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2024 earnings per share estimates for Ovid Therapeutics in a research report issu
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
10:11am, Tuesday, 14'th May 2024
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago.
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
08:00am, Tuesday, 14'th May 2024
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and br
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
07:00am, Monday, 13'th May 2024
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Friday, 26'th Apr 2024
Ovid Therapeutics (OVID) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
10:48am, Tuesday, 09'th Apr 2024
Ovid Therapeutics results from the phase 3 Skyline study, using soticlestat for the treatment of patients with Dravet Syndrome, expected by or before September of 2024. The global Dravet Syndrome mark
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
08:00am, Thursday, 04'th Apr 2024
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
08:00am, Friday, 08'th Mar 2024
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
08:00am, Wednesday, 28'th Feb 2024
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 06'th Feb 2024
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
01:33pm, Thursday, 09'th Nov 2023
Ovid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
08:00am, Friday, 03'rd Nov 2023
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies